健康去哪儿
健趣网登录 关闭
还没有账号?立即注册

Examining the Role of Improved NSAID Management in Treating Dysmenorrhea and Bladder Pain

赞助:
合作者:
信息的提供 (责任方):
Frank F. Tu,NorthShore University HealthSystem Research Institute
October 4, 2018
October 5, 2018
October 5, 2018
May 9, 2018
May 1, 2020   (主要结果测量的最终数据收集日期)
Menstrual Pain[ Time Frame: 6-8 months ]
Daily Diary data on menstrual pain-is it improved with the use of naproxen?

Bladder Pain[ Time Frame: 6-8 months ]
Experimental Bladder Pain sensitivity using a naturalistic paradigm-is it improved when menstrual pain is treated with naproxen?

与当前相同
  • [ Time Frame: ]
 
Examining the Role of Improved NSAID Management in Treating Dysmenorrhea and Bladder Pain
Examining the Role of Improved NSAID Management in Treating Dysmenorrhea and Bladder Pain

The goal of this study is to see if optimized use of naproxen for treatment of dysmenorrhea will improve pain report from baseline. In addition, we will determine whether cross-organ influences from the uterus on bladder pain sensitivity change from baseline after reduced menstrual pain experience over six months. Finally, a battery of quantitative sensory tests and EEG measures of sensory sensitivity will be used to evaluate mechanisms associated with improvements in menstrual and bladder pain.

Interventional
Phase 4
分配:
干预模型: Single Group Assignment
干预模型描述:
盲法: Interventional
盲法描述:
主要目的: Treatment
  • Drug: Naproxen
    Participants will take naproxen 500mg BID before and for the first 3 days of their period.
  • Experimental: Primary Dysmenorrhea
    We will look at the effects of naproxen 500mg use on pain starting just before and during menses.
 
Recruiting
30
与当前相同
May 1, 2021
May 1, 2020   (主要结果测量的最终数据收集日期)
Inclusion Criteria: Reproductive-age women (age 18-45) with dysmenorrhea will be recruited. Cases will have: a) average menstrual pain ≥ 5/10 (0=no pain and 10=the worst imaginable pain) on at least one day during menses or during withdrawal uterine bleeding from cyclic OCs without painkillers, b) menstrual pain in the region between the umbilicus and the perineum, above the level of the inguinal ligament, and c) indication the participant has attempted to resolve pain by medical means (including NSAIDs and/or OCPs). Participants who endorse bladder symptoms (subclinical urgency, frequency, bladder pain) on the phone screen or bladder symptoms will represent at least 50% of enrolled participants); those who do not endorse bladder symptoms may be determined ineligible. They must not have a formal urological diagnosis such as overactive bladder or painful bladder syndrome. Exclusion Criteria: Includes: a) presence of active pelvic or abdominal malignancies (primary or metastatic), b) absence of regular menses (including current pregnancy, recent pregnancy, or active breast feeding), c) active genitourinary infection in the last four weeks, d) unable to read or comprehend the informed consent in English, e) unwilling to complete study procedures, and f) presence of hypertension or risk for developing hypertension, g) unwillingness to take naproxen and/or placebo, h) or contradictions to taking naproxen (allergies, kidney disease, anemia, alcoholism, cardiovascular disease, stomach or intestinal ulcer or abnormal liver function). Participants with a history of epilepsy will not complete the visual unpleasantness task.
参与研究的性别: Female
最小年龄:18 Years ,最大年龄:45 Years  
没有
United States
 
No
研究美国FDA监管的药品: Yes
研究涉及美国FDA监管的设备产品: No
计划分享 IPD:
Frank F. Tu,NorthShore University HealthSystem Research Institute
NorthShore University HealthSystem Research Institute
Principal Investigator: Frank Tu, MD, MPH NorthShore University HealthSystem
NorthShore University HealthSystem Research Institute
October 2018

ICMJE     国际医学期刊编辑委员会和 世界卫生组织 ICTRP 要求的元素
请使用微信扫码报名